SAB Biotherapeutics
SABSSAB Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multi-specific, high-potency human immunoglobulin G (hIgG) therapies.
Table of contents
Earnings
Next report
Aug 6, 2026 (In 1 week)Competitors
By market cap
Profile
SAB Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of multi-specific, high-potency human immunoglobulin G (hIgG) therapies. The company utilizes a proprietary genetic engineering platform to produce human antibodies in large quantities without the need for human donors, focusing on disease-modifying treatments for immune and autoimmune disorders.
SAB Biotherapeutics maintains a unique competitive moat through its Tc-Bovine platform, which lacks a defined biosimilar pathway and eliminates reliance on human plasma donors.
Questions, answered.
- What is SAB Biotherapeutics's market cap?
- SAB Biotherapeutics (SABS) has a market capitalization of $263.0M and trades on NASDAQ.
- Who are SAB Biotherapeutics's competitors?
- SAB Biotherapeutics's key competitors include Shattuck Labs, Inc. Common Stock, Q32 Bio Inc. Common Stock, Avalo Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Where is SAB Biotherapeutics headquartered?
- SAB Biotherapeutics is headquartered in United States of America and employs approximately 57 people. It has been publicly traded since 2021.